XXXX for recurrent surgery and radiation refractory high-grade @entity1653 .

@entity1 @entity137 @entity417 @entity1862 @entity1295 @entity1653
@entity1862 (HU), an orally administered chemotherapy, has become the de facto standard chemotherapeutic agent in @entity1 with surgically and radiation refractory @entity1653 based on a limited literature. A retrospective case series of 35 @entity1 with recurrent WHO Grade 2 (n = 22) or 3 (n = 13) @entity1653 treated with HU following progression after surgery and radiotherapy was collated with primary study objectives of overall response rate, median and progression free survival (PFS) at 6-months. Thirty-five @entity1 (25 @entity1 ; 10 @entity1 : median age 63 years, range 34-86) with recurrent high-grade @entity1653 were treated with HU (1,000 mg/m(2) orally divided twice per day; one cycle operationally defined as 4 weeks of daily HU). @entity1 had progressed radiographically after prior therapy with surgery (35/35) and radiotherapy (35/35: external beam radiotherapy 35/35; stereotactic radiotherapy 35/35). No @entity1 received prior chemotherapy or targeted therapy before instituting HU. @entity1 received 0.5-7 cycles (median 2.0) of HU with modest @entity137 (28.5% all grades and 8.5% grade 3+ @entity417 or @entity1295 ). There were no radiographic responses, 43% of @entity1 had stable disease and 57% manifested progressive disease at first evaluation. The overall PFS was 3.0% at 6 months (median PFS 2.0 months; 95% CI 1.6-2.4). The majority of @entity1 (80%) following progression on HU were subsequently treated on an investigational trial. In this retrospective series, HU though well tolerated and convenient appeared to have very limited activity, raise questions of what constitutes effective salvage therapy and indicates an unmet need for alternative treatments for recurrent high-grade @entity1653 .
